英文名称 | TTT-3002 |
---|---|
别名 | TTT3002 |
英文别名 | TTT3002 |
INCHI | InChI=1S/C27H23N5O3/c1-26-27(28,25(34)29-2)11-18(35-26)31-16-9-5-3-7-13(16)20-21-15(12-30-24(21)33)19-14-8-4-6-10-17(14)32(26)23(19)22(20)31/h3-10,18H,11-12,28H2,1-2H3,(H,29,34)(H,30,33)/t18-,26+,27-/m0/s1 |
---|---|
InChi Key | DCAYZGCTSXLIHO-FYCNXDEQSA-N |
Canonical SMILES | CNC(=O)[C@@]1(N)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O |
PubChem CID | 92136143 |
ChEBI | CHEBI:88219 |
---|---|
PubChem CID | 92136143 |
Reactome Reaction | R-HSA-9702508, R-HSA-9695828 |
Reactome Drug | R-ALL-9702989 |
Ligand ID | 11134 |
---|---|
名称 | TTT-3002 |
别名 | TTT3002 |
类别 | Synthetic organic |
学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
生物活性评价 |
The antiproliferative activity of TTT-3002 in cancer cell lines is more potent in FLT3-dependent cells (those with activating mutations or high levels of WT expression and autocrine activation) compared to FLT3-independent cell lines |
评价 |
TTT-3002 is an experimental indolocarbazole kinase inhibitor. It was originally reported as a LRRK2 inhibitor (including activity against the G2019S and R1441C mutations) |
1. Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H et al.. (2013) Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.. Hum Mol Genet, 22 (2): (328-44). [PMID:23065705] |
2. Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, Levis M, Rudek M, Duffield A, Small D. (2014) TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.. Blood, 123 (10): (1525-34). [PMID:24408321] |
3. Ma HS, Nguyen B, Duffield AS, Li L, Galanis A, Williams AB, Brown PA, Levis MJ, Leahy DJ, Small D. (2014) FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.. Cancer Res, 74 (18): (5206-17). [PMID:25060518] |